Señales en vivo de BSLN.SW | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 11:30):

Stats
Volumen de hoy	22 003.00
Volumen promedio	36 390.00
Capitalización de mercado	478.93M
EPS	CHF0 ( 2024-02-13 )
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	46.40
ATR14	CHF0.109 (0.27%)

Volumen Correlación

Largo: -0.03 (neutral)

Corto: -0.36 (neutral)

Signal:(51.368) Neutral

Basilea Pharmaceutica AG Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Basilea Pharmaceutica AG Correlación - Moneda/Commodity

0.31
( neutral )

0.50
( weak )

0.00
( neutral )

-0.68
( moderate negative )

-0.59
( weak negative )

Basilea Pharmaceutica AG Finanzas

Annual	2023
Ingresos:	CHF157.63M
Beneficio Bruto:	CHF130.84M (83.00 %)
EPS:	CHF0.870

FY	2023
Ingresos:	CHF157.63M
Beneficio Bruto:	CHF130.84M (83.00 %)
EPS:	CHF0.870

FY	2022
Ingresos:	CHF147.77M
Beneficio Bruto:	CHF120.96M (81.86 %)
EPS:	CHF1.020

FY	2021
Ingresos:	CHF148.12M
Beneficio Bruto:	CHF124.05M (83.75 %)
EPS:	CHF-0.664

Financial Reports:

No articles found.

Basilea Pharmaceutica AG

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.